logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem

Small Cap689 EmployeesIPO 2021
Current Price
1137.60
6.1 (0.54%)Updated
NSE :TATVA
BSE :543321
Sector :Chemicals
Today's Range
1105.10
1137.60
union icon
1149.40
52 Week Range
52W Low621.00
52W High1610.00
1137.60
union icon
Downside83.19%
Upside41.53%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
2,836.64 Cr
Market Cap
Total market value of company
P/E Ratio
84.57
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.14
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
14.01
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
1.47%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
1.20%
ROCE
Return on Capital Employed. >15% is good
Net Margin
6.83%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-32.20%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
7.77%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
10.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
27.60%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.05
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
315.84
Book Value
Net asset value per share
Dividend Yield
0.13%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
72.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • Strong promoter holding of 72% indicates high insider confidence and stability.
  • Very low debt-to-equity ratio of 0.05 ensures robust financial health.

Weaknesses

5 points
  • Extremely high P/E ratio of 449.00 suggests significant overvaluation, increasing investment risk.
  • Very low Return on Equity (0.78%) indicates poor efficiency in generating shareholder profits.

Opportunities

4 points
  • Robust global demand for specialty chemicals presents significant market expansion avenues.
  • Investing in R&D for new high-margin specialty chemicals can capture emerging needs.

Threats

5 points
  • Intense competition from larger peers like Pidilite and Atul threatens market share.
  • Extremely high PE ratio (449.00) makes stock vulnerable to re-evaluation and corrections.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

StandaloneAnnualAll amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R41244.90+₹107.30+9.43%
R31200.60+₹63.00+5.54%
R21175.00+₹37.40+3.29%
R11156.30+₹18.70+1.64%
PIVOT1130.70-6.90-0.61%
CURRENT1137.60--
S11023.40-₹114.20-10.04%
S21067.70-₹69.90-6.14%
S31086.40-₹51.20-4.50%
S41112.00-₹25.60-2.25%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.48L
(06 Mar 2026)
-22.2% vs avg
Delivery %
38.0%
(06 Mar 2026)
-5.0% vs avg
Avg Volume (20D)
0.61L
(06 Feb - 06 Mar)
20-day average
Avg Delivery %
43.0%
(06 Feb - 06 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Asian Paints Ltd
2.34L ₹ Cr
Best Profit Growth
Yasho Industries Ltd
248.00 %
Highest Dividend Yield
Vidhi Specialty Food Ingredients Ltd
2.91 %

Peer Comparison

Company Name
ADVENZYMES
Advanced Enzyme Technologies Ltd
ASIANPAINT
Asian Paints Ltd
CAMLINFINE
Camlin Fine Sciences Ltd
FCL
Fineotex Chemical Ltd
FOSECOIND
Foseco India Ltd
JUBLCPL
Jubilant Agri & Consumer Products Ltd
KIRIINDUS
Kiri Industries Ltd
PLATIND
Platinum Industries Ltd
ROSSARI
Rossari Biotech Ltd
RPEL
Raghav Productivity Enhancers Ltd
SHK
S H Kelkar & Company Ltd
VIDHIING
Vidhi Specialty Food Ingredients Ltd
XPROINDIA
XPRO India Ltd
YASHO
Yasho Industries Ltd

About

TATVA

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Limited (TCPL) is a prominent Indian manufacturer and supplier of specialty chemicals, catering to both domestic and international markets. Their business model centers on providing high-quality, specialized chemical compounds for a diverse range of industrial applications. This specialization distinguishes them within the broader chemical industry, allowing them to focus on niche markets and develop strong expertise in their chosen areas.

A core component of TCPL's product portfolio lies in structure-directing agents (SDAs) used in the synthesis of zeolites. Zeolites are crystalline aluminosilicate minerals with various industrial applications, and TCPL's SDAs play a crucial role in controlling the structure and properties of these materials. This demonstrates their involvement in a technologically advanced segment of the chemical industry requiring sophisticated chemical engineering and synthesis expertise.

Beyond zeolite synthesis, TCPL produces and distributes a wide array of other specialty chemicals. This includes phase-transfer catalysts, which accelerate chemical reactions; electrolyte salts for cutting-edge energy storage technologies like supercapacitors and zinc-ion batteries; and various pharmaceutical and agrochemical products. This broad product range underscores their ability to adapt to evolving market demands and serve multiple sectors.

The company's customer base spans a multitude of industries, highlighting the versatility of their chemical offerings. These include the automotive sector, refineries, pharmaceutical manufacturers, agrochemical producers, manufacturers of paints and coatings, dyes and pigments, personal care products, and companies in the flavor and fragrance industries. This widespread reach indicates the diverse applications of their specialized chemicals and their success in penetrating significant market segments.

In summary, Tatva Chintan Pharma Chem Limited operates a successful business focused on the manufacturing and sale of high-value specialty chemicals. Their expertise in specific areas, coupled with a diversified customer base and a broad product portfolio, positions them as a significant player within the global chemical industry. The company's continued focus on innovation and adaptation to emerging technological needs ensures their continued relevance and growth prospects within the market.

COMPANY FACTS - TATVA

Registered Address

Plot No. 353 G.I.D.C, Makarpura

Vadodara

GUJARAT

IN

Company Details

Group: Materials

Sector: Materials

Industry: Chemicals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 689

IPO Date: 29/07/2021

MANAGEMENT - TATVA

Mr. Chintan Shah

Executive Chairman of the Board, Managing Director

Mr. Ashok Bothra

Chief Financial Officer

Mr. Ishwar Nayi

Compliance Officer, Company Secretary

Mr. Ajaykumar Patel

Whole Time Director

Mr. Shekhar Somani

Whole Time Director

Dr. Manher Desai

Non-Executive Independent Director

Mr. Subhash Patel

Non-Executive Independent Director

Dr. Avani Umatt

Non-Executive Independent Director

Investor Questions Answered

Tatva Chintan Pharma Chem Ltd (TATVA) Stock FAQs

Get answers to the most common questions about Tatva Chintan Pharma Chem Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,137.6. Today, the stock has gained by ₹6.10 (0.54%), trading in a range of ₹1,105.1 to ₹1,149.4. The stock opened at ₹1,125.8 with a trading volume of 47,549 shares.
Tatva Chintan Pharma Chem Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,836.64 crores, P/E ratio of 84.57, ROE of 1.47%, and ROCE of 1.20%. The dividend yield stands at 0.13%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,610, while the 52-week low is ₹621. Currently trading at ₹1,137.6, the stock is 52.2% away from its 52-week low and 29.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Tatva Chintan Pharma Chem Ltd stock at ₹1,137.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 84.57 and P/B ratio of N/A. Today's performance shows a gain of 0.54%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Tatva Chintan Pharma Chem Ltd offers a dividend yield of 0.13%, which means for every ₹100 invested at the current price of ₹1,137.6, you can expect to receive approximately ₹0.13 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Tatva Chintan Pharma Chem Ltd's key financial metrics include: P/E Ratio: 84.57, P/B Ratio: N/A, ROE: 1.47%, ROCE: 1.20%, Dividend Yield: 0.13%, EPS: ₹14.01, Book Value: ₹315.84, Debt-to-Equity: 0.05, and Current Ratio: N/A. The company's market cap stands at ₹2,836.64 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Tatva Chintan Pharma Chem Ltd stock opened at ₹1,125.8 and is currently trading at ₹1,137.6, showing a gain of ₹6.10 (0.54%). The intraday high is ₹1,149.4 and low is ₹1,105.1. The trading volume stands at 47,549 shares, indicating moderate market participation today.
Tatva Chintan Pharma Chem Ltd has a Price-to-Earnings (P/E) ratio of 84.57, which means investors are willing to pay ₹84.57 for every ₹1 of earnings. With an EPS of ₹14.01, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Tatva Chintan Pharma Chem Ltd has a market capitalization of ₹2,836.64 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,137.6) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Tatva Chintan Pharma Chem Ltd has a book value of ₹315.84 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,137.6, which is 260.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Tatva Chintan Pharma Chem Ltd has a Return on Equity (ROE) of 1.47% and Return on Capital Employed (ROCE) of 1.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Tatva Chintan Pharma Chem Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Tatva Chintan Pharma Chem Ltd has a debt-to-equity ratio of 0.05, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Tatva Chintan Pharma Chem Ltd has an Earnings Per Share (EPS) of ₹14.01, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,137.6 and P/E ratio of 84.57, investors are paying 84.57 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Tatva Chintan Pharma Chem Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Tatva Chintan Pharma Chem Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Tatva Chintan Pharma Chem Ltd stock, consider: 1) Fundamental Analysis - Review P/E (84.57), ROE (1.47%), debt-to-equity (0.05), and growth rates. 2) Technical Analysis - Check 52-week range (₹621.00 - ₹1610.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1137.60) with book value (₹315.84) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Tatva Chintan Pharma Chem Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,137.6 is 11276x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Tatva Chintan Pharma Chem Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹621.00 - ₹1610.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.05 indicates leverage. 4) Liquidity Risk - Based on trading volume of 47,549 shares. 5) Valuation Risk - P/E of 84.57 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Tatva Chintan Pharma Chem Ltd operates in the industry with key metrics: P/E ratio of 84.57, ROE of 1.47%, market cap of ₹2,836.64 crores, and dividend yield of 0.13%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.05), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Tatva Chintan Pharma Chem Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,137.6, with a 52-week range of ₹621.00 to ₹1610.00. Based on fundamentals like P/E (84.57), ROE (1.47%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Tatva Chintan Pharma Chem Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1137.60. 2) Fundamental Deterioration - Declining ROE (currently 1.47%), increasing debt (D/E: 0.05), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Tatva Chintan Pharma Chem Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.13%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.